The announcement of Dewpoint Therapeutics $100M partnership Bayer to research new treatments for cardiovascular and gynecological diseases has received significant […]

BERLIN / BOSTON, November 14, 2019 – Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, […]

Dewpoint congratulates our scientific founder, Richard Young, on being named to the National Academy of Medicine.

BERLIN / BOSTON, September 23, 2019 –  Rounding out a year of tremendous growth on two continents, Dewpoint Therapeutics, the biomolecular condensates company, has […]

The announcement of the launch of Dewpoint Therapeutics, with $60 Million Series A funding has received significant attention from media […]

CAMBRIDGE, Mass. January 30, 2019 – Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched […]